Continuum Advisory’s TG Therapeutics TGTX Stock Holding History

Continuum Advisory’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15	Closed	-$591	–	1453
2025 Q1	$591	Buy	+15	New	+$505	﹤0.01%	1566

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Continuum Advisory's TGTX Position: Q2 2025 in Review

Continuum Advisory sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 15 shares — an estimated $591 sold.

Continuum Advisory first reported a position in TGTX in Q1 2025 and held it in 1 quarter. The position peaked at $591 in Q1 2025. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

Continuum Advisory reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
Continuum Advisory sold 15 TG Therapeutics shares in Q2 2025, an estimated $591.
Continuum Advisory first reported a position in TG Therapeutics in Q1 2025 and held it in 1 quarter.
Continuum Advisory's TG Therapeutics position peaked at $591 in Q1 2025.
356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.